Last updated on October 2017

A Phase III Study to Evaluate the Efficacy and Safety of GSK1358820 in Subjects With Post-stroke Upper Limb Spasticity


Brief description of study

Botulinum toxin A (GSK1358820) is a sterile, purified type A botulinum neurotoxin complex. In Japan, 240 units of botulinum toxin A are approved as a maximum dose per administration for upper limb spasticity. This study is planned to evaluate the effectiveness and safety of 400 units of botulinum toxin A which can help to increase the maximum dose per administration to 400 units from 240 units as the treatment with 240 units is considered insufficient in subjects with post-stroke upper limb spasticity. Approximately 120 subjects will be randomized to receive either 400 or 240 units of botulinum toxin A in double blind phase followed by open-label phase in which 400 units of the study treatment will be injected in both the groups. The study period will be up to 52 weeks, consisting of a screening phase up to 4 weeks, minimum 12-week double blind phase (Part 1), maximum 36- week open-label phase (12 weeks per cycle with 3 treatment phases: Part 2, Part 3 and Part 4).

Clinical Study Identifier: NCT03261167

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

US GSK Clinical Trials Call ...

GSK Investigational Site
Aichi, Japan
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Fukuoka, Japan
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Hiroshima, Japan
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Hokkaido, Japan
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Hyogo, Japan
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Ibaraki, Japan
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Kanagawa, Japan
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Kumamoto, Japan
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Nagano, Japan
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Okayama, Japan
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Osaka, Japan
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Saga, Japan
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Shizuoka, Japan
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Tokyo, Japan
  Connect »

US GSK Clinical Trials Call ...

GSK Investigational Site
Yamagata, Japan
  Connect »